Condition: Amyotrophic Lateral Sclerosis · Frontotemporal Dementia · Sponsor: Transposon Therapeutics, Inc.
This is a Phase 2a study to assess the the safety and tolerability of TPN-101 in patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated with Hexanucleotide Repeat Expansion in the C9orf72 gene (C9ORF72 ALS/FTD).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of California San Diego | La Jolla, California, United States | — |
| University of California Irvine - ALS & Neuromuscular Center | Orange, California, United States | — |
| UCSF Neurosciences Clinical Research Unit (NCRU) | San Francisco, California, United States | — |
| John Hopkins University | Baltimore, Maryland, United States | — |
| Johns Hopkins Outpatient Center | Baltimore, Maryland, United States | — |
| Massachusetts General Hospital (MGH) - Amyotrophic Lateral Sclerosis (ALS) Multidisciplinary Clinic | Boston, Massachusetts, United States | — |
| Mayo Family Clinic Northwest | Rochester, Minnesota, United States | — |
| Hospital for Special Surgery | New York, New York, United States | — |
| Columbia University Medical Center - The Neurological Institute of New York | New York, New York, United States | — |
| The University of North Carolina at Chapel Hill, Department of Neurology | Chapel Hill, North Carolina, United States | — |
| VIB-KU Leuven Center for Brain & Disease Research | Leuven, Flemish Brabankt, Belgium | — |
| CHU Lille - CMRR Hôpital Roger Salengro | Lille, France | — |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04993755